Stocksigma LogoStocksigma Logo

Gland Pharma Q2FY27 Results: PAT Surges 58% YoY Driven By CDMO Growth

Gland Pharma reported strong Q2FY27 consolidated performance, with revenue rising 23% YoY to ₹18,336 Mn and PAT surging 58% YoY to ₹2,908 Mn, expanding PAT

Gland Pharma Q2FY27 Results: PAT Surges 58% YoY Driven By CDMO Growth

Gland Pharma Ltd · Press Release · 06 Nov 2026, 10:22 pm

Gland Pharma Q2FY27 Results: PAT Surges 58% YoY Driven By CDMO Growth Gland Pharma reported strong Q2FY27 consolidated performance, with revenue rising 23% YoY to ₹18,336 Mn and PAT surging 58% YoY to ₹2,908 Mn, expanding PAT margins by ~350 bps YoY to 16%. Adjusted EBITDA increased 50% YoY to ₹5,030 Mn with a 27% margin. Growth was led by the CDMO segment (+31% YoY to ₹8,227 Mn) and core US markets (+42% YoY to ₹11,795 Mn). R&D stood at ₹1,077 Mn (6% of revenue). In quality audits, USFDA cleared VSEZ with zero observations and Dundigal with four procedural observations.

Original exchange filing (PDF)

More announcements from Gland Pharma Ltd

All Gland Pharma Ltd announcements